BibTex format
@article{Siddiqui:2026:10.1016/j.waojou.2026.101457,
author = {Siddiqui, SH and Ding, B and Dolin, P and Edmonds, C and Jain, P and Rowell, J and Westerink, L and Lacetera, A and Suárez-Sánchez, P and Ariti, C and Podmore, B and Kitchin, Velarde A and Chen, SY},
doi = {10.1016/j.waojou.2026.101457},
journal = {World Allergy Organ J},
title = {Healthcare resource utilisation and associated costs in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.},
url = {http://dx.doi.org/10.1016/j.waojou.2026.101457},
volume = {19},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Real-world data on the healthcare resource utilisation (HCRU) and cost burden of eosinophilic granulomatosis with polyangiitis (EGPA) are limited. We assessed all-cause HCRU and costs in patients with EGPA versus a matched general population cohort without EGPA and a severe uncontrolled asthma (SUA) cohort. METHODS: Primary care data in England from the Clinical Practice Research Datalink Aurum database, with linkage to Hospital Episode Statistics inpatient, outpatient and emergency department records, were analysed. Patients with a new EGPA diagnosis in 2006-2020 and ≥ 1 year of data before diagnosis (index date [ID]) were included and matched using a matching ratio of up to 1:4 with a general population cohort without EGPA and patients with SUA. Follow-up was from ID until deregistration, last data collection, death or study end. HCRU and associated costs were assessed across the 12 months prior to ID, and annually from ID to end of the study period, and by disease states and Five-Factor Score [FFS]. RESULTS: A total of 486 patients with EGPA were identified, with a corresponding matched general population cohort of 1938 and SUA cohort of 1005 patients. Annual all-cause HCRU rates during follow-up were higher in the EGPA cohort versus the general population and SUA cohorts for all types of care, particularly in the first year after ID. Patients with an FFS of 0 generally had lower HCRU than those with an FFS ≥1. Annualised total HCRU-associated costs (95% confidence interval [CI]) were higher in the EGPA cohort (£13,978 [12,068, 15,888]) versus the general population (£2303 [2145, 2461]) and matched SUA cohorts (£3571 [3326, 3816]), with cost ratios (95% CI) of 8.3 (7.1, 9.6) and 4.1 (3.6, 4.6) respectively, both p < 0.0001. The greatest cost driver was hospital admissions with cost ratios (95% CI) of 12.3 (9.8, 15.5) and 5.8 (4.7, 7.2) compared with the general population and SUA cohorts, respectively. Median all-cause annua
AU - Siddiqui,SH
AU - Ding,B
AU - Dolin,P
AU - Edmonds,C
AU - Jain,P
AU - Rowell,J
AU - Westerink,L
AU - Lacetera,A
AU - Suárez-Sánchez,P
AU - Ariti,C
AU - Podmore,B
AU - Kitchin,Velarde A
AU - Chen,SY
DO - 10.1016/j.waojou.2026.101457
PY - 2026///
SN - 1939-4551
TI - Healthcare resource utilisation and associated costs in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.
T2 - World Allergy Organ J
UR - http://dx.doi.org/10.1016/j.waojou.2026.101457
UR - https://www.ncbi.nlm.nih.gov/pubmed/42733590
VL - 19
ER -